Saturday, July 09, 2011 1:27:26 AM
Nice to know the timeframe for things. I couldn't find much on what is the actual polymer or size of the nanoparticle they're using. You mentioned "PEG" so I'm guessing they have something similar to what's described in this Korean paper. Unfortunately my library (University of Chicago) doesn't have online access to it.
http://www.springerlink.com/content/l14482q3830820j1/
Here is another paper providing good overview of polymeric micelles for drug delivery, which NNVC says always could be an additional possibility for their technology, to have a drug delivery in the core, in addition to the micelle which binds to the viral protein, folds over the viral surface, and appears to effectively inactivate / hide the virus. Where the nanoparticle goes in the body depends on the size of the particle, which makes sense.
http://www.iupac.org/publications/pac/2004/pdf/7607x1321.pdf
I assume this is an orally delivered compound, not an injection?
[Edit] Nevermind, here is a nice overview describing the technology, which says will be injectable.
http://www.nanoviricides.com/Antiviral_Therapeutics_technologies_markets_and_companies_January_2008.pdf
The Scully Ebola poster mentioned the compounds have "some toxicity associated with higher concentrations..." but this is pretty vague, and you can't really see any numbers on their graphs.
I guess I'll just have to wait for the tox studies and Phase I results. But I'll keep looking.
http://www.springerlink.com/content/l14482q3830820j1/
Here is another paper providing good overview of polymeric micelles for drug delivery, which NNVC says always could be an additional possibility for their technology, to have a drug delivery in the core, in addition to the micelle which binds to the viral protein, folds over the viral surface, and appears to effectively inactivate / hide the virus. Where the nanoparticle goes in the body depends on the size of the particle, which makes sense.
http://www.iupac.org/publications/pac/2004/pdf/7607x1321.pdf
I assume this is an orally delivered compound, not an injection?
[Edit] Nevermind, here is a nice overview describing the technology, which says will be injectable.
http://www.nanoviricides.com/Antiviral_Therapeutics_technologies_markets_and_companies_January_2008.pdf
The Scully Ebola poster mentioned the compounds have "some toxicity associated with higher concentrations..." but this is pretty vague, and you can't really see any numbers on their graphs.
I guess I'll just have to wait for the tox studies and Phase I results. But I'll keep looking.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
